Document ID: EPA-HQ-OPP-2005-0495-0025
Agency: epa
Document Type: Supporting & Related Material
Title: 
Posted Date: 2006-01-03T05:00Z

Imazapyr
Reader
=

s
Guide
Reader
=

s
Guide
to
Imazapyr
E­
Docket
#
OPP­
2005­
0495
EPA
has
created
this
document
to
provide
an
organizational
structure
to
the
imazapyr
e­
Docket.
The
docket
index
organizes
and
explains
related
documents.
The
first
group
contains
the
Federal
Register
and
Docket
Organizational
Documents;
the
second
group
contains
the
Human
Health
Risk
Assessment
documents
for
Phase
3
Public
Comments;
the
third
group
contains
the
Environmental
Fate
and
Effects
Risk
Assessment
documents
for
Phase
3
Public
Comments.
The
Agency
is
providing
the
A
Reader
=

s
Guide
@

to
allow
the
reader
to
more
easily
access
and
navigate
the
various
items
contained
in
the
imazapyr
e­
docket.

Federal
Register
and
Docket
Organizational
Documents:

Docket
Item
1:
Federal
Register
Notice:
Imazapyr
Risk
Assessment
and
Related
Documents
(
Phase
3
of
4­
Phase
Process);
Notice
of
Availability
This
notice
announces
that
the
risk
assessments
are
available
for
public
review
and
comment.

Docket
Item
2:
Request
for
Additional
Information
and
Suggestions
for
the
Reregistration
of
Imazapyr
Phase
3
Public
Comment
Period
This
document
request
data
and
mitigation
proposals
from
the
public
for
the
reregistration
of
imazapyr.

Docket
Item
3:
Reader
=

s
Guide
to
the
Imazapyr
E­
Docket
#
OPP­
2005­
0495
The
reader
=

s
guide
is
designed
to
give
a
brief
description
of
all
the
imazapyr
documents
in
the
imazapyr
e­
Docket.

Use
Profile:

Docket
Item
4:
Imazapyr
Use
Closure
Memo
This
document
clarifies
imazapyr
uses
for
the
Reregistration
Eligibility
Decision
(
RED)
risk
assessment.
Imazapyr
Reader
=

s
Guide
Human
Health
Risk
Assessment
Documents
for
Phase
3
Public
Comments:

Docket
Item
5:
Imazapyr.
The
Health
Effects
Division=
s
(
HED=
s)
Response
to
Comments
Submitted
During
Phase
One
of
the
Public
Participation
Process.
December
8,
2005
B
Christina
Jarvis
This
document
is
the
Agency
=

s
response
to
error
only
comments.

Docket
Item
6:
Imazapyr:
HED
Chapter
of
the
Reregistration
Eligibility
Document
(
RED).
PC
Code:
128821,
CAS
Reg
81334­
34­
1,
Case
#
3078,
DP
Barcode:
D320583
December
8,
2005
B
Christina
Jarvis
This
document
describes
all
the
human
health
risk
from
the
use
of
imazapyr.

Docket
Item
7:
Imazapyr:
Summary
of
Product
Chemistry
Data
for
Reregistration
Eligibility
Decision
(
RED)
Document
August
29,
2005
B
P.
Yvonne
Barnes
This
document
describes
the
product
chemistry
review,
data
requirements,
and
data
gaps
for
imazapyr.

Docket
Item
8:
Imazapyr.
Chronic
Dietary
Exposure
Assessment
for
the
Section
3
Registration
Action
on
Grasses
and
Aquatic
Sites.
March
26,
2003
B
William
Donovan
This
document
describes
the
chronic
dietary
(
food
&
drinking
water)
exposure
results
and
characterization
for
imazapyr.

Docket
Item
9:
Imazapyr:
Occupational
and
Residential
Exposure
Assessment
for
the
Reregistration
Eligibility
Decision
Document.
August
31,
2005
B
Charles
Smith
This
document
describes
the
occupational
and
residential
exposure
results
and
characterization
for
imazapyr.
Imazapyr
Reader
=

s
Guide
Environmental
Fate
and
Effects
Documents
for
Phase
3
Public
Comment:

Docket
Item
10:
Response
to
Error
Only
Comments
on
the
EFED
Ecological
Risk
Assessment
Supporting
the
Reregistration
Eligibility
Decision
for
the
Herbicide,
Imazapyr
December
9,
2005
B
Stephen
Carey,
Pamela
Hurley,
and
Lucy
Shanaman
This
document
is
the
Agency
=

s
response
to
error
only
comments.

Docket
Item
11:
Level
1
Screening
Ecological
Risk
Assessment
for
the
Reregistration
of
Imazapyr
December
9,
2005
B
Stephen
Carey,
Pamela
Hurley,
and
Lucy
Shanaman
This
document
describes
all
the
ecological
risks
from
the
use
of
imazapyr.

Docket
Item
12:
APPENDIX
A
Environmental
Fate
Summaries
and
Structures
of
Imazapyr
Transformation
Products­
Level
1
Screening
Ecological
Risk
Assessment
for
the
Reregistration
of
Imazapyr
December
9,
2005
B
Stephen
Carey,
Pamela
Hurley,
and
Lucy
Shanaman
This
document
summarizes
the
environmental
fate
of
imazapyr.

Docket
Item
13:
APPENDIX
B
Aquatic
Exposure
Modeling
for
Terrestrial
Applications
(
GENEEC2)
­
Level
1
Screening
Ecological
Risk
Assessment
for
the
Reregistration
of
Imazapyr
December
9,
2005
B
Stephen
Carey,
Pamela
Hurley,
and
Lucy
Shanaman
This
document
summarizes
the
environmental
concentrations
of
imazapyr
for
terrestrial
applications
of
imazapyr.

Docket
Item
14:
APPENDIX
C
Calculation
Methods
and
GENEEC2
Model
Input/
Output
Tables
Showing
Estimated
Environmental
Concentrations
(
EECs)
for
Direct
Application
to
Water­
Level
1
Screening
Ecological
Risk
Assessment
for
the
Reregistration
of
Imazapyr
December
9,
2005
B
Stephen
Carey,
Pamela
Hurley,
and
Lucy
Shanaman
This
document
describes
the
environmental
concentrations
for
direct
application
of
imazapyr
to
bodies
of
water.
Docket
Item
15:
APPENDIX
D
T­
REX
Model
(
T­
REX
Version
1.1)
 
Model
Overview
and
Results­
Level
1
Screening
Ecological
Risk
Assessment
for
the
Reregistration
of
Imazapyr
December
9,
2005
B
Stephen
Carey,
Pamela
Hurley,
and
Lucy
Shanaman
This
document
describes
the
risk
quotient
(
RQ)
results
for
birds
and
mammals.

Docket
Item
16:
APPENDIX
E
Ecological
Effects
Data
­
Level
1
Screening
Ecological
Risk
Assessment
for
the
Reregistration
of
Imazapyr
December
9,
2005
B
Stephen
Carey,
Pamela
Hurley,
and
Lucy
Shanaman
This
document
describes
the
ecological
effects
data
for
imazapyr.

Docket
Item
17:
Appendix
F
TerrPlant
1.0
Modeling
and
Results
­
Level
1
Screening
Ecological
Risk
Assessment
for
the
Reregistration
of
Imazapyr
December
9,
2005
B
Stephen
Carey,
Pamela
Hurley,
and
Lucy
Shanaman
This
document
describes
the
risk
quotient
(
RQ)
results
for
plants.

Docket
Item
18:
APPENDIX
G
The
Risk
Quotient
Method
and
Levels
of
Concern
­
Level
1
Screening
Ecological
Risk
Assessment
for
the
Reregistration
of
Imazapyr
December
9,
2005
B
Stephen
Carey,
Pamela
Hurley,
and
Lucy
Shanaman
This
document
describes
the
levels
of
concern
for
aquatic
and
terrestrial
organisms.

Docket
Item
19:
APPENDIX
H
Summary
of
Endangered/
Threatened
Species
­
Level
1
Screening
Ecological
Risk
Assessment
for
the
Reregistration
of
Imazapyr
December
9,
2005
B
Stephen
Carey,
Pamela
Hurley,
and
Lucy
Shanaman
This
document
lists
the
threatened
and
endangered
species
for
imazapyr.

Docket
Item
20:
APPENDIX
J
Incident
Reports
­
Level
1
Screening
Ecological
Risk
Assessment
for
the
Reregistration
of
Imazapyr
December
9,
2005
B
Stephen
Carey,
Pamela
Hurley,
and
Lucy
Shanaman
This
document
describes
the
incidents
involving
imazapyr.
Docket
Item
21:
APPENDIX
K
Environmental
Fate
and
Monitoring
Bibliography
­
Level
1
Screening
Ecological
Risk
Assessment
for
the
Reregistration
of
Imazapyr
December
9,
2005
B
Stephen
Carey,
Pamela
Hurley,
and
Lucy
Shanaman
This
document
lists
the
fate
data
for
imazapyr.

Docket
Item
22:
Appendix
M
AgDrift
Model
(
spray
drift
estimates)
­
Level
1
Screening
Ecological
Risk
Assessment
for
the
Reregistration
of
Imazapyr
December
9,
2005
B
Stephen
Carey,
Pamela
Hurley,
and
Lucy
Shanaman
This
document
describes
the
spray
drift
estimates
for
imazapyr.

Docket
Item
23:
APPENDIX
N
IMAZAPYR­
Level
1
Screening
Ecological
Risk
Assessment
for
the
Reregistration
of
Imazapyr
December
9,
2005
B
Stephen
Carey,
Pamela
Hurley,
and
Lucy
Shanaman
This
document
describes
the
ecological
papers
that
were
acceptable
for
the
imazapyr
risk
assessment.

Docket
Item
24:
APPENDIX
L
ECOTOXICOLOGY
BIBLIOGRAPHY­
Level
1
Screening
Ecological
Risk
Assessment
for
the
Reregistration
of
Imazapyr
December
9,
2005
B
Stephen
Carey,
Pamela
Hurley,
and
Lucy
Shanaman
This
document
lists
the
ecological
effects
studies
for
imazapyr.

Docket
Item
25:
APPENDIX
I
Data
Requirement
Tables
 
Environmental
Fate
and
Effects­
Level
1
Screening
Ecological
Risk
Assessment
for
the
Reregistration
of
Imazapyr
December
9,
2005
B
Stephen
Carey,
Pamela
Hurley,
and
Lucy
Shanaman
This
document
describes
the
ecological
data
requirements
for
imazapyr.

Docket
Item
26:
Tier
1
Drinking
Water
Exposure
Assessment
for
Imazapyr
November15,
2004
B
R.
David
Jones
This
document
represents
the
Agency
=

s
current
drinking
water
exposure
assessment
for
imazapyr.